source
- Eli Lilly to acquire cancer cell therapy startup Kelonia Therapeutics for $3.2 billionEli Lilly announced it will buy privately held Kelonia Therapeutics, a biotech focused on cell therapies for cancer and autoimmune diseases, in a deal valued at $3.2 billion. Kelonia has operated…
- European regulators recommend Sanofi's MS drug tolebrutinib for approval after US rejectionEuropean Medicines Agency officials issued a positive recommendation for tolebrutinib, an experimental multiple sclerosis therapy from Sanofi, after the U.S. FDA rejected the drug earlier this year…